Skip to main content
OpenTrials
Completed

NCT Number: NCT05072574

Quality of Life, Nutritional Status and Functional Capacity in People With Advanced Chronic Kidney Disease

This study evaluates the clinical response (quality of life, nutritional status, functional capacity, and disease knowledge) of advanced CKD patients who undergo an individualized dietary intervention and a nutritional education program (group workshops) using motivation coaching techniques, compared to controls who receive general hygiene-nutritional education at every visit.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Randomized study including two parallel groups: patients from the advanced chronic kidney disease (CKD) consulting room of the Malaga University Regional Hospital and controls. The main objective is to assess the clinical response (quality of life, nutritional status, functional capacity, and disease knowledge) of advanced CKD patients who undergo an individualized dietary intervention and a nutritional education program (group workshops) using motivation coaching techniques, compared to controls who receive general hygiene-nutritional education at every visit.

Both groups will be composed of 54 participants. The control group will be provided general dietary and lifestyle recommendations (standard procedure in the nephrology consulting room), whereas the intervention group will receive treatment and individualized dietary follow-up using coaching techniques, supported by information and communication technologies, and will participate in a nutritional education program composed of four on-line sessions.

Two visits (basal and three months after) will be scheduled during the study to obtain and analyse the data. Moreover, in these visits researchers will collect a blood sample in order to perform an assessment of the metabolism, inflammation, and oxidation, and a stool sample in order to evaluate the gut microbiota.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients >18 years old with advanced CKD (GFR <30ml/min) starting follow-up in the advanced CKD consulting room of the Malaga University Regional Hospital and who clearly understand the study and give their informed consent.

Exclusion criteria

  • Patients presenting any of these conditions:
  • Active cancer
  • Being already participants of another study that may affect the results
  • Pregnancy or possible pregnancy
  • Informed consent refusal
  • Hospital admission during one month previous to the study
  • Severe mental disorders (SMD), prolonged mental disorders involving a high level of disability and social dysfunction, which requires attendance by the mental health and social care network
  • Alcohol or any other substance abuse that, in the researcher's opinion, may interfere with the study

Treatment and study plan

Specific dietary treatment and follow-up using coaching techniques

Other

Intervention group will receive specific dietary treatment and follow-up using coaching techniques, supported by new technologies, and will attend a nutritional education program

Primary outcomes

  1. Assess the clinical response after the quality of life intervention

    Time frame: From baseline to week 12

    Kidney Disease and Quality of Life test (KDQOL-36). The generic component of the KDQOL-36 (items 1-12) is the SF-12, which allows obtaining 2 general scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). The specific component of the KDQOL-36 (items 13-36), allows obtaining the scores of the specific subscales for the disease.

Secondary outcomes

  1. Assess the clinical response after intervention in the management of CKD

    Time frame: From baseline to week 12

    Self-Efficacy for Managing Chronic Disease test. The Self-Efficacy Scale for the Management of Chronic Diseases (SEMCD) is made up of 6 items on an analog scale, ranging from 1 (not at all sure) to 10 (totally safe).

    The Spanish version (SEMCD-S) consists of 4 items. A higher number means greater self-efficacy. The scale score is the mean of the items.

  2. Assess the clinical response after the intervention in knowledge about the disease

    Time frame: From baseline to week 12

    Kidney Disease Knowledge Survey test. The Kidney Disease Knowledge Survey (KiKS) instrument consists of 28 items and aims to assess specific knowledge about chronic kidney disease in non-dialysis patients. One point is considered for each correct answer and zero for the incorrect one. The total score is calculated by adding all the correct points and divided by 28, obtaining a value from 0 to 1, with 1 being the highest level of knowledge.

  3. BMI (body mass index) changes

    Time frame: From baseline to week 12

    Measured by body composition analysis

  4. Change in weight

    Time frame: From baseline to week 12

    Weight in kg

  5. Change in fat free body mass

    Time frame: From baseline to week 12

    Fat free body mass in kg assessed by bioelectrical impedance analysis

  6. Change in upper arm circumference

    Time frame: From baseline to week 12

    circumference in cm

  7. Change in arm muscle circumference

    Time frame: From baseline to week 12

    circumference in cm

  8. waist circumference

    Time frame: From baseline to week 12

    circumference in cm

  9. Change in serum potassium concentration (assess kidney function)

    Time frame: From baseline to week 12

    serum potassium in mEq/l

  10. Change in serum phosphorus concentration (assess kidney function)

    Time frame: From baseline to week 12

    serum phosphorus mg/dl

  11. Change in glomerular filtration (assess kidney function)

    Time frame: From baseline to week 12

    Calculated with the formula of CKD-EPI and MDRD and measured in ml/ min/ 1.73 m2

  12. Change in serum albumin concentration

    Time frame: From baseline to week 12

    Serum albumin in g/dl

  13. Change in serum prealbumin concentration

    Time frame: From baseline to week 12

    Serum prealbumin in mg/dl

  14. Change in cholesterol concentration

    Time frame: From baseline to week 12

    Serum cholesterol in mg/dl

  15. Change in HDL concentration

    Time frame: From baseline to week 12

    Serum HDL in mg/dl

  16. Change in LDL concentration

    Time frame: From baseline to week 12

    Serum LDL in mg/dl

  17. Change in TG concentration

    Time frame: From baseline to week 12

    Serum TG in mg/dl

  18. Changes in plasma levels of high sensitivity C reactive protein (hs-CRP)

    Time frame: From baseline to week 12

    Plasma levels of high sensitivity C reactive protein (hs-CRP) in mg/dl

  19. Changes in blood cells

    Time frame: From baseline to week 12

    Blood count

  20. Change in iron concentration

    Time frame: From baseline to week 12

    Serum iron in μg/dl

  21. Change in ferritin concentration

    Time frame: From baseline to week 12

    Serum ferritin in ng/ml

  22. Change in uric acid concentration

    Time frame: From baseline to week 12

    Serum uric acid in mg/dl

  23. Change in urea concentration

    Time frame: From baseline to week 12

    Serum uric acid in mg/dl

  24. Change in magnesium concentration

    Time frame: From baseline to week 12

    Serum magnesium in mg/dl

  25. Change in calcium concentration

    Time frame: From baseline to week 12

    Serum calcium in mg/dl

  26. Change in intact parathyroid hormone (PTHi) concentration

    Time frame: From baseline to week 12

    Serum intact parathyroid hormone (PTHi) in pg/ml

  27. Changes in vitamin D

    Time frame: From baseline to week 12

    Serum vitamin D in ng/ml

  28. Changes in metabolic control

    Time frame: From baseline to week 12

    Measured as HbA1c (glycated hemoglobin)

  29. Assess changes in the degree of depression and / or anxiety

    Time frame: From baseline to week 12

    HADS depression and anxiety symptoms screening test. It is a self-administered scale with 14 items divided into 2 subscales (anxiety and depression) whose maximum score is 21 points for each of them. Based on the score obtained, the patients can be classified as normal (<7), doubtful (between 8 and 10) and potential clinical case (≥ 11). The score is referred to the last week.

  30. Assess the clinical response after the intervention on functional capacity

    Time frame: From baseline to week 12

    Scale of autonomy for activities of daily life "Barthel test". This test measures the capacity of the person to carry out ten basic activities of daily life, obtaining a quantitative estimate of the degree of dependence of the subject. The range of possible IB values is between 0 and 100, with 5-point intervals for the original version. The closer a subject's score is to 0, the more dependency they have; the closer to 100 the more independence.

  31. Assess on functional capacity

    Time frame: From baseline to week 12

    Physical activity test "Short Physical Performance Battery" SPPB. This in turn includes 3 tests: balance, gait speed and getting up and sitting in a chair 5 times. Each test is scored from 0 (worst performance) to 4 (best performance): for the balance test according to a hierarchical combination of performance in the 3 component subtests and for the other 2 tests a score of 0 is assigned to those who do not complete or they attempt the task and scores from 1 to 4 based on the time spent. In addition, a total score for the entire battery is obtained, which is the sum of the 3 tests and ranges from 0 to 12.

  32. Changes on functional capacity: International Physical Activity Questionnaire (IPAQ)

    Time frame: From baseline to week 12

    The International Physical Activity Questionnaire (IPAQ) will be used to evaluate the current physical activity level of the participants. The survey consists of 27 questions and 5 parts.

  33. Change from Handgrip Strength

    Time frame: From baseline to week 12

    Strength will be recorded by Jamar Hydraulic Hand Dynamometer (Kg)

  34. Characterize exercise participant behavior

    Time frame: From baseline to week 12

    International Physical Activity Questionnaire (IPAQ). The IPAQ consists of 7 questions about the frequency, duration and intensity of activity (moderate and intense) carried out in the last seven days, as well as walking and sitting time in a work day. It evaluates three characteristics of physics (PA): intensity (mild, moderate or vigorous), frequency (days per week) and duration (time per day). Weekly activity is recorded in Mets (Metabolic Equivalent of Task or Metabolic Index Units) per minute and week.

  35. Change in handgrip strength

    Time frame: From baseline to week 12

    Handgrip strength in kg, measured by the jamar hydraulic hand dynamometer.

  36. Changes the clinical response after the intervention in blood pressure figures (mmHg).

    Time frame: From baseline to week 12

    Assess if syastolic and diastolic pressure improves after training and at 6 months of follow-up.

  37. Diet composition: PREDIMED test (Prevention with Mediterranean Diet)

    Time frame: From baseline to week 12

    Adherence to the Predimed Plus diet pattern 17 (0 - minimum adherence, 17 - maximum adherence)

Sponsors and collaborators

Lead sponsor

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

Other

Registry information

Official study title

Assessment of Quality of Life, Nutritional Status and Functional Capacity in People With Advanced Chronic Kidney Disease (CKD) After the Implementation of a Nutritional Education Plan and Individualized Dietary Intervention

Acronym: ERCANUT

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Oct 11, 2021
Registry last updated
Jul 20, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.